Welcome to our dedicated page for ADMP news (Ticker: ADMP), a resource for investors and traders seeking the latest updates and insights on ADMP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ADMP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ADMP's position in the market.
Adamis Pharmaceuticals (NASDAQ: ADMP) has reacquired marketing rights for SYMJEPI (epinephrine) Injection from Sandoz Inc. and entered a commercialization agreement with US WorldMeds for SYMJEPI and ZIMHI (naloxone) products. The deal involves an upfront payment and milestones totaling up to $26 million, with net profits shared equally after deducting costs. Adamis retains commercialization rights outside the U.S. The transition period will be supported by Sandoz, and Adamis is expected to file its quarterly report by May 2020, reflecting these changes.